HIV: The benefits of prophylaxis of tuberculosis are confirmed

October 11, 2017, ANRS

A long-term follow-up study in the ANRS TEMPRANO trial confirms that tuberculosis chemoprophylaxis in HIV-infected people is more than ever relevant in resource-limited countries. This prophylactic use of drugs reduces mortality, even among people taking antiretroviral treatment who have a high CD4+ T cell count. ANRS TEMPRANO was conducted by researchers of the Ivory Coast ANRS site, which comprises teams from Inserm (U1219, University of Bordeaux), the Infectious and Tropical Diseases Department of the Treichville University Hospital, and eight other infection treatment centers in Abidjan. The results of this trial will be published in the 9 October 2017 issue of The Lancet Global Health and should encourage countries with a heavy tuberculosis burden to apply the relevant WHO recommendations.

Tuberculosis is the leading cause of death among HIV-infected people in sub-Saharan Africa. In the 1990s, several studies showed that HIV-infected people who take the antibiotic isoniazid for six to 12 months are at lower risk of developing . On the basis of these studies, since 1993, the WHO has recommended that people living with HIV in countries where tuberculosis is rife should take isoniazid for six months. However, this recommendation is seldom applied because it was deemed obsolete following the advent of antiretrovirals that restore immunity and hence lower the risk of tuberculosis. ANRS TEMPRANO has reassessed the benefits of isoniazid prophylaxis in the era of early .

ANRS TEMPRANO was conducted between 2008 and 2015, and showed that six-month isoniazid prophylaxis for tuberculosis and early antiretroviral treatment both reduced the risk of severe morbidity in the first two years of follow-up. Published in the New England Journal of Medicine in 2015, these results greatly contributed to the formulation of WHO treatment recommendations. ANRS TEMPRANO participants were then followed up for an average of 4.5 years, and the findings are now published in The Lancet Global Health. This long-term follow-up shows that tuberculosis chemoprophylaxis reduces not only severe morbidity, but also mortality, and that this benefit, which is independent of and complementary to that of antiretroviral , lasts at least six years after administration.

Professor François Dabis, the Director of the ANRS, says, "We now have irrefutable evidence of the value of tuberculosis chemoprophylaxis in HIV-infected people in resource-limited countries in the era of antiretrovirals, even when these are initiated very early. The WHO recommendations should more than ever be applied."

Explore further: HIV: A therapeutic advance for resource-limited settings

More information: Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African HIV-infected adults with high CD4 count: long-term follow up of the Temprano ANRS 12136 trial. Lancet Glob Health 2017; 5: e1080-89

Related Stories

HIV: A therapeutic advance for resource-limited settings

May 29, 2017
ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa (Cameroon, Burkina Faso, and Senegal), shows that dual therapy with lamivudine and a boosted protease inhibitor is effective ...

Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection

July 31, 2017
Robust evidence confirms that most standard treatment regimens currently recommended by the World Health Organization and the Centers for Disease Control and Prevention for latent tuberculosis infection (LTBI), including ...

Assay can ID M. tuberculosis resistance mutations

September 15, 2017
(HealthDay)—An automated molecular assay can detect Mycobacterium tuberculosis with resistance to drugs directly from sputum specimens, according to a study published in the Sept. 14 issue of the New England Journal of ...

Common treatment of TB in advanced HIV patients doesn't save more lives

March 17, 2016
In a report on the so-called REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment) study—a 10-nation, randomized clinical trial of adult outpatients—investigators concluded that there ...

Shorter Combination treatment as effective as monotherapy for TB prevention in kids

January 12, 2015
To prevent tuberculosis (TB) in children with latent tuberculosis infection (which is not active but can become active), combination treatment with the medications rifapentine and isoniazid was as effective as longer treatment ...

Tuberculosis vaccine safe for teens with Schistosoma parasite

May 4, 2017
Of the millions of people at risk for contracting tuberculosis each year, many are already infected with helminths, parasitic worms including Schistosoma flatworms. In some cases, parasite infections can impair the ability ...

Recommended for you

Study predicts 2018 flu vaccine will have 20 percent efficacy

April 19, 2018
A Rice University study predicts that this fall's flu vaccine—a new H3N2 formulation for the first time since 2015—will likely have the same reduced efficacy against the dominant circulating strain of influenza A as the ...

Zika presents hot spots in brains of chicken embryos

April 19, 2018
Zika prefers certain "hot spots" in the brains of chicken embryos, offering insight into how brain development is affected by the virus.

Low-cost anti-hookworm drug boosts female farmers' physical fitness

April 19, 2018
Impoverished female farm workers infected with intestinal parasites known as hookworms saw significant improvements in physical fitness when they were treated with a low-cost deworming drug. The benefits were seen even in ...

Super-superbug clones invade Gulf States

April 18, 2018
A new wave of highly antibiotic resistant superbugs has been found in the Middle East Gulf States, discovered by University of Queensland researchers.

Of mice and disease: Antibiotic-resistant bacteria discovered in NYC house mice

April 17, 2018
A study by scientists at the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health finds New York City house mice carry bacteria responsible for mild to life-threatening gastroenteritis ...

Discovery explains how the chickenpox and shingles virus remains dormant

April 16, 2018
A research team led by UCL and Erasmus University has found a missing piece to the puzzle of why the virus that causes chickenpox and shingles can remain dormant for decades in human cells.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.